Gilles Montalescot

Summary

Country: France

Publications

  1. ncbi request reprint Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, Paris, France
    J Am Coll Cardiol 41:8-14. 2003
  2. doi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
  3. doi request reprint Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
  4. ncbi request reprint High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study
    Gilles Montalescot
    From the ACTION Study Group, Institut de Cardiologie AP HP, INSERM UMRS 1166, Universite Paris 6, Paris, France G M, J S, O B, P S, S A O, M K, J P C Hôpital Louis Pasteur, Le Coudray, France G R Hôpital de la Timone, Marseille, France J L B, T C CH de Bastia, Bastia, France Z B CHU Carémeau, Nimes, France G C CH de la Région Annecienne, Annecy, France L B Hôpital Cardiologique, Lille, France E V B CH de Lagny, Marne la Vallee, France S E Clinique Sainte Clothilde, La Reunion, France C P Hôpital Lariboisière, Paris, France P H CHU Clermont Ferrand, Clermont Ferrand, France P M Hôpital de Rangueil, Toulouse, France D C Unite de Recherche Clinique, Germany
    Circulation 129:2136-43. 2014
  5. pmc Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
    Johanne Silvain
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    BMJ 344:e553. 2012
  6. ncbi request reprint Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay
    J Abtan
    Gilles Montalescot, MD, PhD, bureau 236, Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France, Tel 33 142163006, Fax 33 142162931, E mail
    Thromb Haemost 110:1055-64. 2013
  7. doi request reprint Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière ACTION group, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 6, Paris, France
    N Engl J Med 369:999-1010. 2013
  8. doi request reprint Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Am Heart J 165:515-22. 2013
  9. ncbi request reprint Current antiplatelet options for NSTE-ACS patients
    G Cayla
    Institut de Cardiologie, bureau 236, Pitie Salpetriere University Hospital, 47 83, bld de l Hôpital, 75013 Paris, France
    QJM 105:935-48. 2012
  10. pmc Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells
    Seraya Maouche
    INSERM UMR S525, Faculte de Medecine Pierre et Marie Curie, Universite Paris VI, 91 Boulevard de l Hopital, Paris 75634 Cedex 13, France
    BMC Genomics 9:302. 2008

Detail Information

Publications129 found, 100 shown here

  1. ncbi request reprint Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, Paris, France
    J Am Coll Cardiol 41:8-14. 2003
    ....
  2. doi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
    ..Our purpose was to evaluate long-term mortality and identify factors associated with 1-year mortality in patients who underwent elective percutaneous coronary intervention (PCI)...
  3. doi request reprint Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
    ..We compared traditional heparin treatment with intravenous enoxaparin in primary PCI...
  4. ncbi request reprint High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study
    Gilles Montalescot
    From the ACTION Study Group, Institut de Cardiologie AP HP, INSERM UMRS 1166, Universite Paris 6, Paris, France G M, J S, O B, P S, S A O, M K, J P C Hôpital Louis Pasteur, Le Coudray, France G R Hôpital de la Timone, Marseille, France J L B, T C CH de Bastia, Bastia, France Z B CHU Carémeau, Nimes, France G C CH de la Région Annecienne, Annecy, France L B Hôpital Cardiologique, Lille, France E V B CH de Lagny, Marne la Vallee, France S E Clinique Sainte Clothilde, La Reunion, France C P Hôpital Lariboisière, Paris, France P H CHU Clermont Ferrand, Clermont Ferrand, France P M Hôpital de Rangueil, Toulouse, France D C Unite de Recherche Clinique, Germany
    Circulation 129:2136-43. 2014
    ..Whether results are different during the phase of secondary prevention starting after hospital discharge, when periprocedural events have been excluded, is unknown...
  5. pmc Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
    Johanne Silvain
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    BMJ 344:e553. 2012
    ..To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention...
  6. ncbi request reprint Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay
    J Abtan
    Gilles Montalescot, MD, PhD, bureau 236, Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France, Tel 33 142163006, Fax 33 142162931, E mail
    Thromb Haemost 110:1055-64. 2013
    ..In conclusion, ELISA-VASP is a fast, easy-to-use and specific test to identify HPR in ACS patients on thienopyridines. A 60% threshold value displays the best accuracy to identify HPR in these patients. ..
  7. doi request reprint Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière ACTION group, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 6, Paris, France
    N Engl J Med 369:999-1010. 2013
    ..We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated...
  8. doi request reprint Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Am Heart J 165:515-22. 2013
    ..The primary safety end point is major, life-threatening, or minor bleeding after ticagrelor administration. The results of this study may have an impact on future recommendations for treatment for patients with STEMI...
  9. ncbi request reprint Current antiplatelet options for NSTE-ACS patients
    G Cayla
    Institut de Cardiologie, bureau 236, Pitie Salpetriere University Hospital, 47 83, bld de l Hôpital, 75013 Paris, France
    QJM 105:935-48. 2012
    ....
  10. pmc Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells
    Seraya Maouche
    INSERM UMR S525, Faculte de Medecine Pierre et Marie Curie, Universite Paris VI, 91 Boulevard de l Hopital, Paris 75634 Cedex 13, France
    BMC Genomics 9:302. 2008
    ..In addition, a reference list of differentially expressed genes (DEG) was generated from a larger number of hybridizations (mRNA from 86 individuals) using the RNG/MRC two-color platform...
  11. doi request reprint Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  12. ncbi request reprint Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study
    Gilles Montalescot
    Institut de Cardiologie AP HP, INSERM U856 and Universite Paris 6, Hopital Pitie Salpetriere, Paris, France
    Thromb Haemost 103:213-23. 2010
    ..Thus, in ACS patients a prasugrel 10-mg MD regimen resulted in significantly greater platelet inhibition than clopidogrel at twice its approved MD or a 900-mg LD...
  13. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  14. doi request reprint Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, AP HP, and INSERM Unit 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Int J Cardiol 150:79-83. 2011
    ....
  15. doi request reprint Platelet biology and implications for antiplatelet therapy in atherothrombotic disease
    Gilles Montalescot
    Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Clin Appl Thromb Hemost 17:371-80. 2011
    ..We expect that this new approach may mitigate bleeding risk, because PAR-1 is not essential for hemostasis...
  16. ncbi request reprint Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up
    Gilles Montalescot
    Institute of Cardiology APHP and INSERM unit 856, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 28:443-9. 2007
    ..We performed a meta-analysis on case specific data of primary stenting in STEMI with a long-term evaluation...
  17. ncbi request reprint A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Gilles Montalescot
    Institut de Cardiologie Pitié Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris APHP, Paris, France
    J Am Coll Cardiol 48:931-8. 2006
    ..We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs)...
  18. pmc Unprotected left main revascularization in patients with acute coronary syndromes
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Blvd de l Hopital, 75013 Paris, France
    Eur Heart J 30:2308-17. 2009
    ....
  19. ncbi request reprint Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    JAMA 302:947-54. 2009
    ..International guidelines recommend an early invasive strategy for patients with high-risk acute coronary syndromes without ST-segment elevation, but the optimal timing of intervention is uncertain...
  20. doi request reprint Mechanical reperfusion: treat well, treat on time too
    Gilles Montalescot
    INSERM U 856, Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Paris 6, Paris 75013, France
    Lancet 372:509-10. 2008
  21. doi request reprint A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study
    Gilles Montalescot
    Hopital de la Pitie Salpetriere, Paris, France
    Am Heart J 161:650-656.e1. 2011
    ..Prasugrel, a novel thienopyridine, is an appropriate drug to address this issue as it provides predictably high and rapid inhibition of platelet aggregation...
  22. ncbi request reprint STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
    Gilles Montalescot
    Institut de Cardiologie and INSERM U856, Pitie Salpetriere University Hospital, AP HP, 47 Boulevard de l Hopital, Paris 75013, France
    Eur Heart J 28:1409-17. 2007
    ..The aim of this study was to describe the management and outcomes using 'real-world' data taking the new definition of acute myocardial infarction into account...
  23. ncbi request reprint Switching acute coronary syndrome patients from prasugrel to clopidogrel
    Mathieu Kerneis
    Institut de Cardiologie, Institut National de la Sante et de la recherche Medicale UMRS937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    JACC Cardiovasc Interv 6:158-65. 2013
    ..This study sought to assess the consequences of switching prasugrel to clopidogrel on platelet inhibition and clinical outcomes after an acute coronary syndrome (ACS)...
  24. doi request reprint Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM U856 and University of Paris 6, Pitie Salpetriere Hospital, Paris, France
    Am J Cardiol 104:904-9. 2009
    ..In conclusion, high hospital levels of CITP, a marker of collagen degradation and ventricular remodeling, are associated with late mortality and other serious clinical events after AMI...
  25. doi request reprint Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM U937 and Univ Paris 6, Pitie Salpetriere Hospital, Paris, France
    Catheter Cardiovasc Interv 79:104-12. 2012
    ..We evaluated the incidence, types, and prognostic impact of bleeding complications in a non-selected patient population with ongoing STEMI treated with aggressive antithrombotic treatment and routine radial primary PCI...
  26. doi request reprint High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
    Jean Philippe Collet
    Institut de Cardiologie, INSERM CMR937, Hôpital Pitié Salpêtrière Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie UPMC, Paris VI, Paris, France
    JACC Cardiovasc Interv 4:392-402. 2011
    ..This study sought to determine whether the pharmacokinetic (PK) and pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) differ according to CYP2C19*2 allele...
  27. ncbi request reprint Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE)
    Gilles Montalescot
    Service de cardiologie, Pitie Salpetriere Hospital, Paris, France
    Catheter Cardiovasc Interv 60:360-7. 2003
    ..4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%)...
  28. doi request reprint A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)
    Jean Philippe Collet
    Institut de Cardiologie, INSERM UMRS937, hôpital Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France ACTION Study Group, Paris, France
    Am J Cardiol 112:1367-72. 2013
    ..36, 95% CI 0.18 to 0.74, p = 0.003). In conclusion, in the per-protocol analysis of the ATOLL trial, pertinent to >87% of the study population, enoxaparin was superior to UFH in reducing ischemic end points and mortality...
  29. ncbi request reprint Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
    Miles Dalby
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    J Am Coll Cardiol 43:162-8. 2004
    ..The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention...
  30. doi request reprint Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates
    Farzin Beygui
    Department of Cardiology and INSERM, Pitié Salpêtrière University Hospital APHP, Paris, France
    Am J Cardiol 106:650-8. 2010
    ..In low-risk populations, a strategy using these biomarkers might help in identifying patients at greater risk of additional events...
  31. doi request reprint Bedside monitoring to adjust antiplatelet therapy for coronary stenting
    Jean Philippe Collet
    Institut de Cardiologie Hôpital Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    N Engl J Med 367:2100-9. 2012
    ..Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy...
  32. doi request reprint [Myocardial infarction: Role of new antiplatelet agents]
    Johanne Silvain
    Universite Paris 6, Institut de Cardiologie, INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Paris, France
    Presse Med 40:615-24. 2011
    ..e. in the elderly patient with comorbidities...
  33. doi request reprint One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent
    Olivier Barthelemy
    Centre Hospitalier Universitaire Pitie Salpetriere, AP HP, Institut de Cardiologie, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 104:604-10. 2011
    ..It is unknown whether the efficacy and safety of drug-eluting stents (DES) apply in patients with chronic renal failure (CRF)...
  34. pmc FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype--phenotype case control study
    Johanne Silvain
    Institut de Cardiologie, INSERM UMRS 937, Pitie Salpetriere Hospital, AP HP, Universite Paris 6, Paris, France
    Thromb Haemost 106:511-20. 2011
    ..01). In conclusion, FXIII-A Leu34 is a polymorphism which provides a strong resistance to fibrinolysis with a gene-dose effect, but does not relate to premature CAD or to recurrent coronary events in this study...
  35. ncbi request reprint Pharmacogenetics of clopidogrel
    Stephen A O'Connor
    Institut de Cardiologie, INSERM U 937, Groupe A C T I O N Groupe Hospitalier Pitié Salpêtrière, 47, Boulevard de l Hopital, 75013 Paris, France
    Curr Pharm Des 18:5309-27. 2012
    ....
  36. doi request reprint Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study
    Anne Bellemain-Appaix
    Institut de Cardiologie INSERM 937, Pitie Salpetriere University Hospital, APHP, Paris, France
    Catheter Cardiovasc Interv 79:823-33. 2012
    ..We sought to compare physical and morphological properties of fibrin clots made in the presence of ioxaglate (ICM), iodixanol (NICM) versus control and to evaluate the effect of four anticoagulants used in PCI...
  37. doi request reprint High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
    Johanne Silvain
    bureau 236, Institut de Cardiologie, INSERM UMRS937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, 47 83 boulevard de l Hopital, Paris, France
    Eur Heart J 33:1241-9. 2012
    ..younger patients (<75 years). Elderly patients represent a growing and challenging segment of the coronary population for whom the effect of dual antiplatelet therapy on platelet inhibition has not been specifically addressed...
  38. doi request reprint CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    Jean Sebastien Hulot
    Universite Pierre et Marie Curie Paris 6, INSERM UMR S 956, Pharmacology Department, Pitie Salpetriere University Hospital, Paris, France
    Circ Cardiovasc Interv 4:422-8. 2011
    ..We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics and the occurrence of cardiovascular outcomes in young post-myocardial infarction (MI) patients treated with clopidogrel...
  39. ncbi request reprint Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study
    Johanne Silvain
    Institut de Cardiologie, Bureau 2 236, INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, 47 83 bld de l Hôpital, 75013 Paris, France
    Eur Heart J 31:2816-21. 2010
    ..The aim of this paper is to determine whether RBC transfusion increases platelet activation and aggregation...
  40. doi request reprint Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test
    Johanne Silvain
    Institut de Cardiologie, Institut National de la Santé et de la Recherche Médicale INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    J Am Coll Cardiol 55:617-25. 2010
    ..This study evaluated the ability of the bedside test Hemochron Jr. Hemonox (International Technidyne Corporation, Edison, New Jersey) to identify patients with insufficient anti-Xa activity level in the catheterization laboratory...
  41. doi request reprint Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
    Jean Sebastien Hulot
    Service de Pharmacologie, Unité de Pharmacogénétique, INSERM UMRS 956, Hopital Pitie Salpetriere, Paris, France
    J Am Coll Cardiol 56:134-43. 2010
    ....
  42. doi request reprint Real-life management of dual antiplatelet therapy interruption: the REGINA survey
    Jean Philippe Collet
    bureau 236, Inserm 937, Institut de Cardiologie, hôpital Pitié Salpêtrière AP HP, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:697-710. 2009
    ..The nationwide REGINA survey was designed to evaluate how the interruption of dual APT is managed in the 'real world'...
  43. doi request reprint Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM CMR937 and Univ Paris 6, Pitie Salpetriere Hospital, Paris, France
    Int J Cardiol 163:266-71. 2013
    ..We aimed to assess whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular (CV) events in stable patients with established atherothrombosis or multiple risk factors...
  44. doi request reprint Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
    Jean Philippe Collet
    Inserm unit 937, Institut de Cardiologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, bureau 236, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:485-96. 2009
    ..Late discontinuation of clopidogrel after an acute coronary syndrome or stent placement may be associated with a clinical rebound effect...
  45. ncbi request reprint Platelet function testing and implications for clinical practice
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    J Cardiovasc Pharmacol Ther 14:157-69. 2009
    ....
  46. doi request reprint Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
    Guillaume Cayla
    Institut de Cardiologie, INSERM Unité Mixte de Recherche_S 937, Pitie Salpetriere Hospital, Paris, France
    JAMA 306:1765-74. 2011
    ..Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI)...
  47. doi request reprint Slow response to clopidogrel predicts low response
    Anne Bellemain-Appaix
    Assistance Publique Hopitaux de Paris, Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    J Am Coll Cardiol 55:815-22. 2010
    ..The purpose of this study was to determine whether the speed of response to clopidogrel loading predicts the final degree of response...
  48. ncbi request reprint Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    Laurent Bonello
    Department of Cardiology, Institut National de la Santè et de la Recherche Médicale Unité Mixte de Recherche 608, Hopital Universitaire Nord, Faculte de Medecine, Marseille, France
    J Am Coll Cardiol 56:919-33. 2010
    ..This review provides a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and proposes how this measurement may be used in the future care of patients...
  49. ncbi request reprint Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow c
    Johanne Silvain
    Institut de Cardiologie, Institut National de la Santé et de la Recherche Médicale CMR937, Allies in Cardiovascular Trials Initiatives and Organized Networks Group, Pitié Salpétrière hospital Assistance Publique Hôpitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    J Am Coll Cardiol 63:1289-96. 2014
    ..This study sought to determine whether red blood cell (RBC) transfusion increases in vivo platelet aggregation and inflammation in coronary and noncoronary patients...
  50. ncbi request reprint Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Groupe Hospitalier Pitié Salpêtrière Hospital, AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    Am J Cardiol 91:925-30. 2003
    ..vWF and its receptor glycoprotein Ib/IX play a key role in acute coronary syndromes. vWF is linked to inflammation and, like glycoprotein Ib/IX, is affected more favorably by the LWMHs than by UFH...
  51. ncbi request reprint Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
    Jean Sebastien Hulot
    Pharmacology Department, Institute of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Clin Pharmacol Ther 77:542-52. 2005
    ..However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment...
  52. pmc Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis
    Paola Sanchez-Pena
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hospitaux de Paris, Paris 6 University, Paris, France
    Br J Clin Pharmacol 60:364-73. 2005
    ..v.) enoxaparin could be used as antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI). However, anti-Xa pharmacokinetics following different i.v. dosing regimens is not clearly established...
  53. ncbi request reprint Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials
    Raphaelle Dumaine
    Centre Hospitalier Universitaire Pitie Salpetriere, Institute of Cardiology, Bureau 2 236, 47 Blvd de l Hopital, 75013, Paris, France
    Arch Intern Med 167:2423-30. 2007
    ..Our objective was to perform a meta-analysis of randomized trials comparing the efficacy and safety of LMWH vs UFH as anticoagulants in the setting of PCI...
  54. pmc Composition of coronary thrombus in acute myocardial infarction
    Johanne Silvain
    Institut de Cardiologie, INSERM UMRS937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    J Am Coll Cardiol 57:1359-67. 2011
    ..We sought to analyze the composition of coronary thrombus in vivo in ST-segment elevation myocardial infarction (STEMI) patients...
  55. doi request reprint Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans o
    Farzin Beygui
    Institut de Cardiologie and INSERM U, Pitie Salpetriere University Hospital, APHP, Paris, France
    Am Heart J 157:680-7. 2009
    ..Whether there is a relationship between aldosterone levels and outcome in a broader spectrum of patients admitted for AMI defined by the new definition based on troponin levels remains unknown...
  56. doi request reprint Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    Jean Philippe Collet
    Institut de Cardiologie, INSERM 856, Universite Paris 6, hôpital Pitié Salpêtrière AP HP, Paris, France
    Lancet 373:309-17. 2009
    ..We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel...
  57. ncbi request reprint A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
    Remi Choussat
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    J Am Coll Cardiol 40:1943-50. 2002
    ....
  58. doi request reprint Antiplatelet options for secondary prevention in acute coronary syndromes
    Johanne Silvain
    INSERM UMRS 937, Pitie Salpetriere Hospital, Institut de Cardiologie, University Paris, Paris 6, France
    Expert Rev Cardiovasc Ther 9:1403-15. 2011
    ..Despite an increase in bleeding risk, prasugrel and ticagrelor appear to have a better net clinical benefit, especially in higher-risk patients with ACS...
  59. ncbi request reprint Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies
    Patrick Goldstein
    SAMU du Nord Emergency Department, Lille University Hospital France, Lille, France
    Eur J Emerg Med 16:244-55. 2009
    ..The experience of several European emergency response systems initiating prehospital treatment, shows that this strategy is highly effective in improving outcomes for patients with acute coronary syndromes...
  60. ncbi request reprint [Anti-thrombotic therapy of acute coronary syndromes without ST elevation]
    Gilles Montalescot
    Institut de Cardiologie, Groupe Hospitalier Pitie Salpetriere, AP HP, 47, Boulevard de l Hopital, 75013 Paris
    Bull Acad Natl Med 189:217-25; discussion 225-6. 2005
    ..Combined antithrombotic therapy also increases the benefit of early invasive strategies including coronary angiogram with stent-based percutaneous coronary angioplasty...
  61. ncbi request reprint Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis
    Maria Borentain
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    Catheter Cardiovasc Interv 65:212-21. 2005
    ..During PCI, intravenous LMWH without coagulation monitoring has the potential to be at least as safe and efficacious as intravenous UFH. Further studies of LMWHs in PCI are therefore required...
  62. ncbi request reprint Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    Gilles Montalescot
    Institute of Cardiology, INSERM U856, Universite Paris 6, Pitié Salpêtrière Hospital AP HP, Paris, France
    Lancet 373:723-31. 2009
    ..Prasugrel, a potent and rapid-acting thienopyridine, is a potential alternative to clopidogrel. We aimed to assess prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) for STEMI...
  63. ncbi request reprint Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference
    Farzin Beygui
    Department of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Circulation 113:e21-3. 2006
  64. doi request reprint New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis
    Anne Bellemain-Appaix
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    J Am Coll Cardiol 56:1542-51. 2010
    ..The purpose of this study was to perform a meta-analysis of randomized trials that compare new P2Y(12) inhibitors with clopidogrel to determine whether they improve clinical outcomes after percutaneous intervention (PCI)...
  65. ncbi request reprint Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
    Jean Philippe Collet
    Department of Cardiology, Centre Hôpital Pitié Salpêtrière, Bureau 2 236, 47, Boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 26:2285-93. 2005
    ..To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status...
  66. ncbi request reprint Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
    Ziad Mallat
    Institut National de la Santé et la Recherche Médicale, INSERM U541, Institut Fédératif de Recherche IRF Circulation, Paris, France
    J Am Coll Cardiol 46:1249-57. 2005
    ..The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS)...
  67. doi request reprint Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study
    Jean Philippe Collet
    Institut de Cardiologie, Unité INSERM 856, Pitié Salpêtrière University Hospital AP HP, Paris, France
    Circulation 118:1225-33. 2008
    ....
  68. doi request reprint Prasugrel monitoring and bleeding in real world patients
    Guillaume Cayla
    Institut de Cardiologie, INSERM UMRS937, Pitie Salpetriere Hospital, Universite Paris 6, Paris, France
    Am J Cardiol 111:38-44. 2013
    ..Minor or minimal bleeding is frequent, but not major bleeding. VASP was poorly correlated with the risk for minor or minimal bleeding...
  69. doi request reprint Feasibility of outpatient coronary angiography with "ad hoc" angioplasty
    Arnaud Chaumeil
    Institute of Cardiology, Pitié Salpêtrière Hospital Group, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Arch Cardiovasc Dis 101:383-90. 2008
    ..It combines the advantages of increased convenience for the patient and lower costs...
  70. doi request reprint Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe
    Patrice P Cacoub
    AP HP Service de Médecine Interne, Groupe Hospitalier La Pitié Salpêtrière, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Heart 97:660-7. 2011
    ..To examine the impact of cardiovascular risk factor control on 3-year cardiovascular event rates in patients with stable symptomatic atherothrombotic disease in Europe...
  71. ncbi request reprint Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin
    Alexandre Ouattara
    Department of Anaesthesiology and Critical Care, Institute of Cardiology, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Université Pierre et Marie Curie Paris, Paris, France
    Eur Heart J 28:1025-32. 2007
    ....
  72. doi request reprint Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial
    Farzin Beygui
    Institut de Cardiologie and INSERM U937, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Am Heart J 160:642-8. 2010
    ..Angiotensin-converting enzyme inhibitors have delayed partial and temporary effects on aldosterone levels. We hypothesize that aldosterone receptor blockade, early after AMI onset on top of standard therapy, may improve clinical outcome...
  73. doi request reprint Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)
    Gilles Montalescot
    Pitie Salpetriere University Hospital, Paris, France
    JACC Cardiovasc Interv 3:203-12. 2010
    ..The aim of this study was to assess the risk-benefit of enoxaparin (Sanofi-Aventis, Paris, France) in primary percutaneous coronary intervention (PCI)...
  74. ncbi request reprint [Platelet aggregation and antiplatelet agents in acute coronary syndromes]
    Jean Philippe Collet
    Institut de Cardiologie, Hopital de la Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Sci (Paris) 20:291-7. 2004
    ..Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients...
  75. doi request reprint Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease
    Farzin Beygui
    Cardiology Department, Pitie Salpetriere University Hospital, Paris, France
    J Heart Lung Transplant 29:316-22. 2010
    ..We aimed to assess the outcome of successful PCI with BMS or drug-eluting stenting (DES) in such patients...
  76. ncbi request reprint Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy
    Jean Philippe Collet
    Pitie Salpetriere University Hospital, Paris, France
    J Am Coll Cardiol 48:1326-35. 2006
    ....
  77. ncbi request reprint The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
    Jean Philippe Collet
    Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Diab Vasc Dis Res 2:136-43. 2005
    ..This review examines all these important issues...
  78. doi request reprint Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
    Jean Philippe Collet
    Institut de Cardiologie, Hopital Pitie Salpetriere, Paris, France
    Am Heart J 161:5-12.e5. 2011
    ..Time and consequence of discontinuation of thienopyridine after stenting is also an unsolved issue after drug eluting stent (DES) implantation...
  79. ncbi request reprint Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment
    Jean Sebastien Hulot
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ther Drug Monit 26:305-10. 2004
    ....
  80. ncbi request reprint Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay
    Patrick Ecollan
    SAMU, Pitie Salpetriere University Hospital, Paris, France
    Int J Cardiol 119:349-54. 2007
    ..To evaluate the diagnostic performance of a portable semi-quantitative whole blood immunoassay measuring soluble human fatty acid-binding protein [H-FABP] (CardioDetect) for the pre-hospital detection of myocardial infarction (MI)...
  81. pmc The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis
    Jean Philippe Collet
    Institut de Cardiologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, France
    Blood 106:3824-30. 2005
    ..In conclusion, these studies provide the first definitive evidence that the alphaC domains play an important role in determining the structure and biophysical properties of clots and their susceptibility to fibrinolysis...
  82. ncbi request reprint Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational global registry of acute coronary events
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié Salptrière, Paris, France
    Am J Cardiol 95:1397-403. 2005
    ....
  83. ncbi request reprint Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis
    Gilles Montalescot
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    JAMA 292:362-6. 2004
    ..No systematic reviews have comprehensively examined the effects of early vs delayed administration of these agents...
  84. doi request reprint Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
    Patrice P Cacoub
    Pierre and Marie Curie University Paris 6, and AP HP, Hospital La Pitié Salpêtrière, Paris, France
    Atherosclerosis 204:e86-92. 2009
    ..To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates...
  85. ncbi request reprint Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis
    Claude Le Feuvre
    Cardiology Department, Pitie Salpetriere Hospital, Paris, France
    Int J Cardiol 109:207-12. 2006
    ..This study aimed to assess the clinical outcome and to analyse predictive factors of cardiac events in patients with in-stent restenosis treated with Sirolimus-eluting stent (SES)...
  86. ncbi request reprint High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction
    Farzin Beygui
    Cardiology Department and INSERM U 856, Pitie Salpetriere University Hospital, Paris, France
    Circulation 114:2604-10. 2006
    ..Whether aldosterone level at presentation for STEMI is associated with adverse outcome remains unknown...
  87. doi request reprint Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
    Gilles Montalescot
    Bureau 2 236, Institut de Cardiologie, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
    Eur Heart J 30:2733-41. 2009
    ..This study investigated the effects of irbesartan vs. enalapril, with early vs. late treatment, on markers of inflammation and ischaemic heart disease in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS)...
  88. ncbi request reprint Images in cardiovascular medicine. Recurrent myocardial infarction in a patient with paroxysmal nocturnal hemoglobinuria
    Fabien Hyafil
    Institute of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Circulation 108:e91-2. 2003
  89. ncbi request reprint Defining standards of care for facilitated and direct percutaneous coronary intervention
    Gilles Montalescot
    Division of Cardiology, Hĵpital la Pitié Salpétrière, Institut de Cardialogie, Paris, France
    Clin Cardiol 25:I27-32. 2002
    ..Since direct PCI is often a slow process, better use of existing and future therapies, as well as advances in patient transport, are expected to improve patient outcomes...
  90. doi request reprint Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants
    Gilles Montalescot
    Institut de Cardiogie, Centre Hospitalier Universitarie Pitié Salpetrèire, Paris, France
    Clin Appl Thromb Hemost 15:183-96. 2009
    ..Future trials should report the rates of periprocedural complications when assessing the safety of novel anticoagulation therapies in PCI...
  91. doi request reprint Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events
    Ph Gabriel Steg
    INSERM U 698 Recherche Clinique en Athérothrombose, université Paris VII Denis Diderot, Assistance Publique Hopitaux de Paris, Centre Hospitalier Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    Eur Heart J 30:321-9. 2009
    ..To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI)...
  92. doi request reprint Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
    Jean Philippe Collet
    Inserm 856 and Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    Int J Cardiol 133:8-17. 2009
    ..g. those who require non-cardiac surgery). This review discusses the benefits and risks of long-term dual antiplatelet therapy in a range of clinical situations...
  93. ncbi request reprint Myocardial infarction after endomyocardial biopsy in a heart transplant patient
    Gerard Drobinski
    Department of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    J Interv Cardiol 15:403-5. 2002
    ....
  94. ncbi request reprint Does preoperative coronary angioplasty improve perioperative cardiac outcome?
    Gilles Godet
    Anesthesiology and Critical Care, Hospitalo Universitaire Pitié Salpêtrière, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Anesthesiology 102:739-46. 2005
    ..However, the impact of this approach on postoperative outcome remains controversial...
  95. doi request reprint Renal function, atherothrombosis extent, and outcomes in high-risk patients
    Raphaelle L Dumaine
    Pitie Salpetriere University Hospital, Paris, France
    Am Heart J 158:141-148.e1. 2009
    ..Although prior data showed an association between chronic kidney disease (CKD) and atherothrombotic events, little is known about the risk profile and specific outcomes of atherothrombotic outpatients with CKD...
  96. doi request reprint [New antiplatelet drugs]
    Anne Bellemain
    Institut de Cardiologie, Unité INSERM 856, Hôpital Pitié Salpêtrière F 75013 Paris, France
    Presse Med 37:1055-68. 2008
    ..But only very recently have new targets been developed. The synergy of their mechanisms of action now makes it possible to obtain ever stronger inhibition of platelet aggregation...
  97. ncbi request reprint Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study)
    Raphaelle Dumaine
    Pitie Salpetriere Hospital, Paris, France
    Am J Cardiol 94:1543-7. 2004
    ..One third of patients with ACS presented with renal insufficiency. After adjustment for potential confounders, decreasing renal function was independently associated with in-hospital death, bleeding, and contrast-induced nephropathy...
  98. ncbi request reprint Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    J Biol Chem 278:21331-5. 2003
    ....
  99. ncbi request reprint Multimodality imaging of percutaneous closure of the left atrial appendage
    Farzin Beygui
    Department of Cardiology, Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 83 Bd de l Hopital, 75013 Paris, France
    Eur Heart J 27:640. 2006
  100. ncbi request reprint Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  101. ncbi request reprint The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...